Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Caladrius Biosciences (CLBS) shares
Learn how to easily invest in Caladrius Biosciences shares.
Caladrius Biosciences is a biotechnology business based in the US. Caladrius Biosciences stocks (CLBS.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.64 – an increase of 7.32% over the previous week. Caladrius Biosciences employs 27 staff and has a market cap (total outstanding stock value) of $25.7 million.
How to buy stocks in Caladrius Biosciences
- Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CLBS – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- Can I buy shares in Caladrius Biosciences?
- Has coronavirus impacted Caladrius Biosciences shares?
- Caladrius Biosciences shares summary
- Compare share dealing platforms
- Is Caladrius Biosciences stock a buy or sell?
- Caladrius Biosciences performance over time
- Caladrius Biosciences's financials
- How volatile are Caladrius Biosciences shares?
- Does Caladrius Biosciences pay a dividend?
- Have Caladrius Biosciences shares ever split?
- Other common questions
Caladrius Biosciences stock price (NASDAQ:CLBS)Use our graph to track the performance of CLBS stocks over time.
Caladrius Biosciences shares at a glance
|Latest market close||$0.44|
|52-week range||$0.40 - $1.68|
|50-day moving average||$0.66|
|200-day moving average||$0.94|
|Wall St. target price||$8.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.50|
Compare stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Caladrius Biosciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Caladrius Biosciences price performance over time
|1 week (2022-05-10)||4.76%|
|1 month (2022-04-13)||-37.14%|
|3 months (2022-02-17)||-42.84%|
|6 months (2021-11-17)||-57.28%|
|1 year (2021-05-17)||-70.47%|
|2 years (2020-05-15)||-75.96%|
|3 years (2019-05-16)||3.1|
|5 years (2017-05-16)||5.37|
Caladrius Biosciences financials
|Gross profit TTM||$0|
|Return on assets TTM||-27.3%|
|Return on equity TTM||-44.21%|
|Market capitalisation||$25.7 million|
TTM: trailing 12 months
Caladrius Biosciences share dividends
We're not expecting Caladrius Biosciences to pay a dividend over the next 12 months.
Have Caladrius Biosciences's shares ever split?
Caladrius Biosciences's shares were split on a 1:10 basis on 27 July 2016. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Caladrius Biosciences shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Caladrius Biosciences shares which in turn could have impacted Caladrius Biosciences's share price.
Caladrius Biosciences share price volatility
Over the last 12 months, Caladrius Biosciences's shares have ranged in value from as little as $0.402 up to $1.68. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Caladrius Biosciences's is 0.9725. This would suggest that Caladrius Biosciences's shares are less volatile than average (for this exchange).
Caladrius Biosciences overview
Caladrius Biosciences, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc.
Caladrius Biosciences in the news
Cable companies to offer effectively free internet to low-income homes
Is Caladrius Biosciences (NASDAQ:CLBS) In A Good Position To Deliver On Growth Plans?
Caladrius Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More on investing
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.Read more…
Here’s what you need to know about investing in the propane industry, including 3 popular propane stocks to watch.Read more…
Using our proprietary algorithm, we’ve found the best blue chip stocks on the TSX, NYSE and Nasdaq based on price, performance and more.Read more…
More guides on Finder
How to buy Hanover Bancorp, Inc. (HNVR) stock in Canada when it goes public
Everything we know about the Hanover Bancorp, Inc. IPO, plus information on how to buy in.
How to buy PrimeBlock stock in Canada when it goes public
Everything we know about the PrimeBlock IPO, plus information on how to buy in.
How to buy Actelis Networks (ASNS) stock in Canada when it goes public
Everything we know about the Actelis Networks IPO, plus information on how to buy in.
How to buy ProFrac Holding Corp (PFHC) stock in Canada when it goes public
Everything we know about the ProFrac Holding Corp IPO, plus information on how to buy in.
How to buy Wytec International (WYTC) stock in Canada when it goes public
Everything we know about the Wytec International IPO, plus information on how to buy in.
Here are some of the best stocks for inflation periods to reduce the negative impacts of inflation on your portfolio.
HSBC InvestDirect Review
Choose from many account and investment types to invest in global markets, but expect to pay high commissions with HSBC InvestDirect, which doesn’t have an app.
Our Flahmingo review tells you how to buy fractional shares of some of your favourite US companies with as little as $1.
How to buy Expeditors International of Washington stock in Canada
Steps to owning and managing EXPD stock, with 24-hour and historical pricing before you buy.
How to buy Perseus Mining stock in Canada
Steps to owning and managing PRU stock, with 24-hour and historical pricing before you buy.